HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supplement OWL Registry Counts On Peer Pressure To Spur Use

This article was originally published in The Rose Sheet

Executive Summary

CRN-organized Supplement OWL launches with nearly 2,600 labels included and adds almost 500 more in its first week, though a much larger total is needed to offer drug store chains and other retailers access a broader perspective of products available in the US.

You may also be interested in...



SSCI Offers Benchmarks As Gatekeepers For Supplements To Reach Retail Shelves

FDA’s GMP final rule set uniform standards to ensure quality throughout manufacturing, packaging, labeling and holding of supplements, but Supplement Safety and Compliance Initiative says manufacturing practices continue to vary widely across the industry and the agency cannot inspect every facility. “FDA can’t solve all our problems. I don’t know if FDA knows the number of facilities it needs to inspect to ensure consumer confidence," says Daniel Fabricant, president of SSCI member NPA.

Abbott Nutrition, FDA Warning, OWL Board: Health And Wellness Industry News

Abbott Nutrition sales flat; Texas herbal coop gets FDA warning; And CRN appoints OWL advisory board.

Hoot For OWL, More Listeria-Linked Recalls: Health & Wellness Industry News

CRN's Supplement OWL American Society of Association Executives recognition; recall of products containing potentially contaminated ingredients from HVF Inc. spreads to Bhu Foods' protein bars.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS026881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel